Tag Archives: ESMO

ESMO: Merck’s Keytruda doubles 5-year survival rate for lung cancer patients

Immuno-oncology competition has mounted this year in previously untreated, metastatic non-small cell lung cancer. But Merck’s Keytruda, the first PD-1/PD-L1 on the market in the setting, has new long-term survival results that the drugmaker hopes will help bolster its position. Keytruda doubled the five-year survival rate for patients whose tumors expressed levels of biomarker PD-L1… Read More »